<ul>
<li>三家医疗巨头刚刚提高了股息——谁支付得最多</li>
</ul>
<p>根据 MarketBeat 的股票筛选工具，Eli Lilly and Company、Alnylam Pharmaceuticals、AbbVie、Insmed、Gilead Sciences、Vertex Pharmaceuticals 和 Pfizer 是今天值得关注的七只制药股票。制药股票是指那些研究、开发、生产和销售处方药、疫苗及相关疗法的上市公司股票。对于投资者而言，这些股票提供了对医疗行业的曝光，受临床试验结果、监管批准、专利保护、药品定价和并购等因素的驱动——这些因素可能带来显著的上涨潜力和明显的波动性。这些公司在过去几天内的交易量是所有制药股票中最高的。</p>
<p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<h2>Eli Lilly and Company (LLY)</h2>
<p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；Zepbound 用于肥胖。</p>
<ul>
<li>Pfizer 加大对减肥药物的投资</li>
</ul>
<p>阅读我们关于 LLY 的最新研究报告</p>
<h2>Alnylam Pharmaceuticals (ALNY)</h2>
<p>Alnylam Pharmaceuticals, Inc.是一家生物制药公司，专注于基于核糖核酸干扰发现、开发和商业化新型治疗药物。其市场产品包括 ONPATTRO（patisiran），用于治疗成人遗传性转甲状腺素介导的淀粉样变性多发性神经病；AMVUTTRA 用于治疗成人 hATTR 淀粉样变性伴多发性神经病；GIVLAARI 用于治疗急性肝卟啉症的成人；OXLUMO 用于治疗原发性高草酸尿症 1 型。</p>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>阅读我们关于 ALNY 的最新研究报告</p>
<h2>AbbVie (ABBV)</h2>
<p>AbbVie Inc.在全球范围内发现、开发、生产和销售药物。该公司提供 Humira，一种用于自身免疫性和肠道 Behçet 病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<p>阅读我们关于 ABBV 的最新研究报告</p>
<h2>Insmed (INSM)</h2>
<p>Insmed Incorporated 是一家全球生物制药公司，致力于改变严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），已在美国获批用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或无替代治疗选择的抗菌药物组合方案的一部分。</p>
<p>阅读我们关于 INSM 的最新研究报告</p>
<h2>Gilead Sciences (GILD)</h2>
<p>Gilead Sciences, Inc.是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
<p>阅读我们关于 GILD 的最新研究报告</p>
<h2>Vertex Pharmaceuticals (VRTX)</h2>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者市场 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者市场 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者市场 ORKAMBI；以及为 1 岁或以上的 CF 患者市场 KALYDECO。</p>
<p>阅读我们关于 VRTX 的最新研究报告</p>
<h2>Pfizer (PFE)</h2>
<p>Pfizer Inc.在美国、欧洲及国际上发现、开发、生产、市场、分销和销售生物制药产品。该公司在各种治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；满足医疗需求的传染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
<p>阅读我们关于 PFE 的最新研究报告</p>
<h2>进一步阅读</h2>
<ul>
<li>MarketBeat 在 2025 年 12 月的五大股票推荐</li>
<li>随着加密货币势头减弱的两只股票</li>
<li>分析师正在升级的三只股息增长股票</li>
<li>这三家银行在年末反弹，但这种趋势会持续吗？</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>这只 ETF 在美联储降息后获得了重大顺风</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Eli Lilly and Company 吗？</h2>
<p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来并不在名单上。</p>
<p>虽然礼来目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

艾伯维

礼来

吉利德科学

<p>MarketBeat 的股票筛选器突出了七只值得关注的制药股票：礼来、Alnylam Pharmaceuticals、艾伯维、Insmed、吉利德科学、福泰制药和辉瑞。这些公司因其高交易量和潜在的显著回报而受到关注，驱动因素包括临床试验结果和监管批准。建议投资者考虑这些股票，以便接触医疗保健行业，该行业既提供机会也伴随波动</p>

<ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——谁支付得最多</li>
</ul>
</div><p>Eli Lilly and Company, Alnylam Pharmaceuticals, AbbVie, Insmed, Gilead Sciences, Vertex Pharmaceuticals, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related therapies. For investors, these stocks provide exposure to the healthcare sector and are driven by factors such as clinical trial results, regulatory approvals, patent protection, drug pricing, and mergers — which can produce both significant upside and pronounced volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p>
<div class="lb-trans"><p>根据 MarketBeat 的股票筛选工具，Eli Lilly and Company、Alnylam Pharmaceuticals、AbbVie、Insmed、Gilead Sciences、Vertex Pharmaceuticals 和 Pfizer 是今天值得关注的七只制药股票。制药股票是指那些研究、开发、生产和销售处方药、疫苗及相关疗法的上市公司股票。对于投资者而言，这些股票提供了对医疗行业的曝光，受临床试验结果、监管批准、专利保护、药品定价和并购等因素的驱动——这些因素可能带来显著的上涨潜力和明显的波动性。这些公司在过去几天内的交易量是所有制药股票中最高的。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><h2>Eli Lilly and Company (LLY)</h2>
<div class="lb-trans"><h2>Eli Lilly and Company (LLY)</h2>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；Zepbound 用于肥胖。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Pfizer 加大对减肥药物的投资</li>
</ul>
</div><p>Read Our Latest Research Report on LLY</p>
<div class="lb-trans"><p>阅读我们关于 LLY 的最新研究报告</p>
</div><h2>Alnylam Pharmaceuticals (ALNY)</h2>
<div class="lb-trans"><h2>Alnylam Pharmaceuticals (ALNY)</h2>
</div><p>Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.</p>
<div class="lb-trans"><p>Alnylam Pharmaceuticals, Inc.是一家生物制药公司，专注于基于核糖核酸干扰发现、开发和商业化新型治疗药物。其市场产品包括 ONPATTRO（patisiran），用于治疗成人遗传性转甲状腺素介导的淀粉样变性多发性神经病；AMVUTTRA 用于治疗成人 hATTR 淀粉样变性伴多发性神经病；GIVLAARI 用于治疗急性肝卟啉症的成人；OXLUMO 用于治疗原发性高草酸尿症 1 型。</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Read Our Latest Research Report on ALNY</p>
<div class="lb-trans"><p>阅读我们关于 ALNY 的最新研究报告</p>
</div><h2>AbbVie (ABBV)</h2>
<div class="lb-trans"><h2>AbbVie (ABBV)</h2>
</div><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc.在全球范围内发现、开发、生产和销售药物。该公司提供 Humira，一种用于自身免疫性和肠道 Behçet 病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><p>Read Our Latest Research Report on ABBV</p>
<div class="lb-trans"><p>阅读我们关于 ABBV 的最新研究报告</p>
</div><h2>Insmed (INSM)</h2>
<div class="lb-trans"><h2>Insmed (INSM)</h2>
</div><p>Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.</p>
<div class="lb-trans"><p>Insmed Incorporated 是一家全球生物制药公司，致力于改变严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），已在美国获批用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或无替代治疗选择的抗菌药物组合方案的一部分。</p>
</div><p>Read Our Latest Research Report on INSM</p>
<div class="lb-trans"><p>阅读我们关于 INSM 的最新研究报告</p>
</div><h2>Gilead Sciences (GILD)</h2>
<div class="lb-trans"><h2>Gilead Sciences (GILD)</h2>
</div><p>Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p>
<div class="lb-trans"><p>Gilead Sciences, Inc.是一家生物制药公司，在美国、欧洲及国际上发现、开发和商业化满足医疗需求的药物。该公司提供 Biktarvy、Genvoya、Descovy、Odefsey、Truvada、Complera/Eviplera、Stribild、Sunlencs 和 Atripla 等产品用于治疗 HIV/AIDS；Veklury，一种用于静脉注射的药物，用于治疗 COVID-19；以及 Epclusa、Harvoni、Vemlidy 和 Viread 用于治疗病毒性肝炎。</p>
</div><p>Read Our Latest Research Report on GILD</p>
<div class="lb-trans"><p>阅读我们关于 GILD 的最新研究报告</p>
</div><h2>Vertex Pharmaceuticals (VRTX)</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals (VRTX)</h2>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者市场 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者市场 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者市场 ORKAMBI；以及为 1 岁或以上的 CF 患者市场 KALYDECO。</p>
</div><p>Read Our Latest Research Report on VRTX</p>
<div class="lb-trans"><p>阅读我们关于 VRTX 的最新研究报告</p>
</div><h2>Pfizer (PFE)</h2>
<div class="lb-trans"><h2>Pfizer (PFE)</h2>
</div><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>Pfizer Inc.在美国、欧洲及国际上发现、开发、生产、市场、分销和销售生物制药产品。该公司在各种治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；满足医疗需求的传染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
</div><p>Read Our Latest Research Report on PFE</p>
<div class="lb-trans"><p>阅读我们关于 PFE 的最新研究报告</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>MarketBeat's Top Five Stocks to Own in December 2025</li>
<li>2 Stocks to Avoid as Crypto Momentum Wanes</li>
<li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 在 2025 年 12 月的五大股票推荐</li>
<li>随着加密货币势头减弱的两只股票</li>
<li>分析师正在升级的三只股息增长股票</li>
<li>这三家银行在年末反弹，但这种趋势会持续吗？</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>这只 ETF 在美联储降息后获得了重大顺风</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Eli Lilly and Company 吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

12 月 21 日值得考虑的制药股票